NCT00993655 2023-08-28
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Canadian Cancer Trials Group
Phase 2 Completed
Clinical Trials
19 trialsNCT00886691 2022-02-04
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT01720173 2021-10-20
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
GOG Foundation
Phase 2 Completed
NCT00030446 2020-04-08
Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT00010179 2020-04-06
Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT00939809 2019-01-15
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00114166 2018-07-24
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00459290 2018-07-18
Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
GOG Foundation
Phase 2 Completed
NCT00499252 2018-01-11
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00574951 2018-01-11
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Terminated
NCT00857545 2017-09-13
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
GOG Foundation
Phase 2 Completed
NCT01039207 2017-09-07
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00872989 2016-12-19
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00671788 2016-04-15
A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
GOG Foundation
Phase 2 Completed
NCT00008138 2016-01-08
S0009
SWOG Cancer Research Network
Phase 2 Completed
NCT00002538 2013-08-20
Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers
GOG Foundation
Phase 2 Completed
NCT00369954 2013-06-10
Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin
GOG Foundation
Phase 2 Withdrawn
NCT00003624 2013-04-11
Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer
GOG Foundation
Phase 2 Terminated
NCT00003896 2013-01-04
S9912 Combination Chemo in Stage III Ovarian Cancer,
SWOG Cancer Research Network
Phase 2 Completed